Enzymatic Bioremodelers

BACKGROUNDThe steady evolution of aesthetic and regenerative medicine has driven a paradigm shift from purely corrective interventions toward biologically oriented therapies focused on tissue remodeling, extracellular matrix modulation, and regenerative optimization. Recent advances in biotechnology and recombinant protein engineering have enabled the development of highly purified enzymes that selectively interact with structural and functional components of the tissue microenvironment. Despite their growing clinical relevance, therapeutic enzymes are still often discussed in isolation, limiting a broader understanding of their shared biological mechanisms and therapeutic potential.

MATERIALS AND METHODSA narrative review was conducted, integrating evidence from molecular biology, extracellular matrix research, fibrosis, adipose tissue physiology, protein therapeutics, regenerative medicine, and aesthetic medicine. In addition to foundational biological studies, recent clinical and translational investigations involving recombinant hyaluronidases, collagenases, lipases, keratinases, and matrix-targeting lyases were analyzed. Evidence from scar management, post-liposuction fibrosis, localized adiposity, cellulite, facial reshaping, foreign body granulomas, periocular edema associated with hyaluronic acid fillers, and biostimulator-related complications was critically reviewed.

RESULTS AND DISCUSSIONThe available evidence demonstrates that therapeutic enzymes share common biological characteristics, including substrate-specific molecular recognition, catalytic activity, and selective modulation of tissue morphology. Clinical studies have reported improvements in fibrosis, scar quality, cellulite, localized fat deposits, facial contouring, tissue laxity, granulomatous reactions, and filler-related complications. Histological analyses additionally support their capacity to reorganize extracellular matrix structures, reduce fibrosis, improve collagen organization, and restore tissue homeostasis. Unlike conventional therapies that rely primarily on inflammation, cytotoxicity, or mechanical disruption, enzyme-based interventions promote targeted biochemical remodeling through precise substrate interactions.

CONCLUSIONThe collective evidence supports the establishment of Enzymatic Bioremodelers as a novel therapeutic category comprising natural or recombinant enzymes that promote selective tissue remodeling using targeted biochemical modulation of the tissue microenvironment. This framework integrates molecular mechanisms with emerging clinical applications, providing a scientifically grounded platform for future developments aesthetic medicine, regenerative medicine, and precision therapeutics.

Abstract from Crossref